$MLYS

Mineralys Therapeutics (MLYS) presented data at the American Heart Association Hypertension Scientific Sessions 2026. In the Launch-HTN trial, 46% of participants with difficult-to-treat hypertension achieved the AHA/ACC systolic blood pressure target of <130 mmHg with lorundrostat 50 mg. In the Explore-OSA trial, lorundrostat reduced morning systolic blood pressure by 11.1 mmHg at Week 4. Both trials showed favorable safety and tolerability profiles for lorundrostat.

Congleton Jon (Chief Executive Officer) sold 75,000 shares of Mineralys Therapeutics, Inc. (MLYS) at $25.46 ($1.91M total) on 2026-09-30 under a Rule 10b5-1 trading plan.

Mineralys Therapeutics (MLYS) will present new data from its Launch-HTN trial of lorundrostat at the American Society of Nephrology Kidney Week 2026. The trial, involving patients with uncontrolled hypertension, showed lorundrostat's potential in reducing blood pressure and albuminuria in chronic kidney disease stages 1-3. The company aims to address hypertension and related comorbidities driven by dysregulated aldosterone.

Slingsby Brian Taylor sold 104,320 indirectly-held shares of Mineralys Therapeutics, Inc. (MLYS) at $28.81 ($3.01M total) on 2026-09-22.

Mineralys Therapeutics (MLYS) officer David Rodman plans to sell 2,171 shares via a cashless option exercise on September 9, 2026, valued at $67,018.77. Rodman has made multiple prior open-market sales, including 14,058 shares on July 13, 2026, for $387,716.51. The transactions are disclosed via Form 144 filings.

Mineralys Therapeutics (MLYS) shares rose after the company acquired future royalty obligations for its lead drug, lorundrostat, potentially increasing long-term profits if approved. Analysts initiated coverage with undervalued ratings, and institutional buying was reported ahead of the FDA's 2026 decision. The stock has fallen 30.37% YTD, with a market cap of $2.27B. Risks include clinical setbacks and financial strain due to cash burn and debt.

Mineralys Therapeutics (MLYS) reported a Q2 2026 net loss of $241.07M. The company appointed James J. Ferguson III, M.D., as Chief Medical Officer. Shares are down 5.04% in 30 days and 14.07% in 90 days, but up 72.32% in 1 year and 97.31% in 3 years. Analysts suggest fair value at $50.88, above the current $25.65, based on lorundrostat's potential. Risks include regulatory outcomes and cash burn.

Mineralys Therapeutics (MLYS) officer Eric Warren filed a Rule 144 notice to sell 7,437 shares on 08/21/2026 via employee stock options. Warren previously sold 104,124 shares for $2.7M on 06/26/2026 and 7,438 shares for $199,884.80 on 07/21/2026. The planned sale is valued at $193,188.40.

Mineralys Therapeutics (MLYS) reported Q2 net loss of $241.07M and appointed James J. Ferguson III, M.D., as Chief Medical Officer. The company secured $150M in equity financing and a $500M loan to support commercialization. Analysts project $215.7M revenue and $23.5M earnings by 2029, with a 91% upside to current price.

Mineralys Therapeutics (MLYS) reported Q2 2026 earnings, highlighting a net loss of $241.1 million due to royalty repurchase obligations. Key financial activities included a $150 million equity offering and a $100 million tranche from a $500 million loan. The company is preparing for the FDA's PDUFA date for lorundrostat, a hypertension treatment, with commercial launch plans and payer discussions underway. Management expressed optimism about the regulatory review and market potential.